研究發現，用於治療感染性腹瀉的抗生素可能是一種有效的炎症性腸病的藥物

英國伯明翰大學的研究人員表明，一種稱為萬古黴素的抗生素也可能有效地治療具有特定類型的人

An antibiotic used to treat infective diarrhoea may be an effective drug for a type of inflammatory bowel disease, according to a new study.

一項新研究顯示，一種用於治療感染性腹瀉的抗生素可能是一種有效的炎症性腸病的有效藥物。

Researchers from the University of Birmingham showed that an antibiotic called vancomycin may also be effective in treating people who have a specific type of inflammatory bowel disease (IBD), which develops due to an incurable autoimmune liver disease called primary sclerosing cholangitis (PSC).

伯明翰大學的研究人員表明，一種稱為萬古黴素的抗生素也可能有效地治療患有特定類型的炎症性腸病（IBD）的人，該抗生素由於可治療的自身免疫性肝臟疾病而發展，該疾病被稱為原發性硬化性膽管炎（PSC）。

Notably, four in five patients who participated in the study achieved remission after taking the drug as part of a clinical trial published in the Journal of Crohn's and Colitis.

值得注意的是，參加該研究的五分之四的患者在將藥物作為克羅恩雜誌和結腸炎雜誌發表的臨床試驗的一部分後獲得了緩解。

The study is significant, as several participants with this disease had not responded to other IBD treatments.

這項研究很重要，因為該疾病的一些參與者未對其他IBD治療做出反應。

Moreover, IBD and PSC are closely correlated, with most individuals who have PSC developing IBD, and up to 14 per cent of patients with IBD also developing PSC.

此外，IBD和PSC密切相關，大多數患有PSC開發IBD的人，而IBD患者中最多也有14％的患者也在發展PSC。

Together, the condition raised the need for colon surgery and or developing colon or liver cancer, which would them need a liver transplant. It also raises the overall risk of death.

這種情況共同提高了結腸手術和或發展結腸或肝癌的需求，它們需要進行肝移植。它還增加了死亡的總體風險。

"Our findings suggest that vancomycin could offer a new therapeutic option for patients with this challenging combination of IBD and autoimmune liver disease," said Dr. Mohammed Nabil Quraishi from the University of Birmingham.

伯明翰大學的Mohammed Nabil Quraishi博士說：“我們的發現表明，萬古黴素可以為IBD和自身免疫性肝病的這種具有挑戰性的患者提供一種新的治療選擇。”

During the trial, participants were treated with oral antibiotics for four weeks. About 80 per cent of patients achieved clinical remission after the treatment.

在試驗期間，將參與者用口服抗生素治療四個星期。治療後，約有80％的患者在臨床緩解中得到了緩解。

They also showed a significant decrease in inflammatory markers, and 100 per cent showed mucosal healing.

它們還顯示出炎症標記的顯著降低，100％顯示粘膜癒合。

However, when the treatment was stopped after 8 weeks, the symptoms returned.

但是，當治療在8週後停止治療時，症狀恢復了。

Vancomycin was also shown to induce changes in certain bile acids, which are now being further investigated to develop and refine treatments for IBD-associated PSC.

Vancomycin還顯示出誘導某些膽汁酸的變化，現在正在進一步研究這些膽汁酸，以開發和完善與IBD相關的PSC的處理。

Although the results are preliminary, they provide a strong foundation for further research, said the team.

該團隊說，儘管結果是初步的，但它們為進一步的研究提供了堅實的基礎。